60 related articles for article (PubMed ID: 15654720)
1. Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021.
Jiang T; Su H; Xu J; Li C; Zhang N; Li Y; Wu Y; Ni R; Ming Y; Li Z; Li L; Liu Y
Ther Adv Drug Saf; 2024; 15():20420986231224227. PubMed ID: 38293566
[TBL] [Abstract][Full Text] [Related]
2. Imaging Biomarkers in Animal Models of Drug-Induced Lung Injury: A Systematic Review.
Mahmutovic Persson I; von Wachenfeldt K; Waterton JC; Olsson LE; On Behalf Of The Tristan Consortium
J Clin Med; 2020 Dec; 10(1):. PubMed ID: 33396865
[TBL] [Abstract][Full Text] [Related]
3. A Multicenter Study of Docetaxel at a Dose of 100 mg/m
Hirata T; Ozaki S; Tabata M; Iwamoto T; Hinotsu S; Hamada A; Motoki T; Nogami T; Shien T; Taira N; Matsuoka J; Doihara H
Intern Med; 2021 Apr; 60(8):1183-1190. PubMed ID: 33191320
[TBL] [Abstract][Full Text] [Related]
4. Interstitial Lung Disease as an Adverse Drug Reaction in Japan: Exploration of Regulatory Actions as a Basis for High Reporting.
Iwasa E; Fujiyoshi Y; Kubota Y; Kimura R; Chandler RE; Taavola H; Norén GN; Wakao R
Drug Saf; 2020 Nov; 43(11):1121-1131. PubMed ID: 32617874
[TBL] [Abstract][Full Text] [Related]
5. Association of HLA-DRB1*04:05 allele with drug-induced interstitial lung disease in Japanese population.
Imatoh T; Ushiki A; Ota M; Ito M; Sekine A; Yamashita T; Mashimo Y; Nakamura R; Saito K; Saito Y; Hanaoka M
Pharmacogenomics J; 2020 Dec; 20(6):823-830. PubMed ID: 32467566
[TBL] [Abstract][Full Text] [Related]
6. Data-Driven Identification of Adverse Event Reporting Patterns for Japan in VigiBase, the WHO Global Database of Individual Case Safety Reports.
Wakao R; Taavola H; Sandberg L; Iwasa E; Soejima S; Chandler R; Norén GN
Drug Saf; 2019 Dec; 42(12):1487-1498. PubMed ID: 31559542
[TBL] [Abstract][Full Text] [Related]
7. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer.
Kawata T; Higashimori M; Itoh Y; Tomkinson H; Johnson MG; Tang W; Nyberg F; Jiang H; Tanigawara Y
Cancer Chemother Pharmacol; 2019 May; 83(5):849-858. PubMed ID: 30762084
[TBL] [Abstract][Full Text] [Related]
9. Drug-Induced Interstitial Lung Disease: A Systematic Review.
Skeoch S; Weatherley N; Swift AJ; Oldroyd A; Johns C; Hayton C; Giollo A; Wild JM; Waterton JC; Buch M; Linton K; Bruce IN; Leonard C; Bianchi S; Chaudhuri N
J Clin Med; 2018 Oct; 7(10):. PubMed ID: 30326612
[TBL] [Abstract][Full Text] [Related]
10. Combination of quercetin, cinnamaldehyde and hirudin protects rat dorsal root ganglion neurons against high glucose-induced injury through Nrf-2/HO-1 activation and NF-κB inhibition.
Shi Y; Liang XC; Zhang H; Sun Q; Wu QL; Qu L
Chin J Integr Med; 2017 Sep; 23(9):663-671. PubMed ID: 28861887
[TBL] [Abstract][Full Text] [Related]
11. Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study.
Osawa M; Kudoh S; Sakai F; Endo M; Hamaguchi T; Ogino Y; Yoneoka M; Sakaguchi M; Nishimoto H; Gemma A
Int J Clin Oncol; 2015 Dec; 20(6):1063-71. PubMed ID: 25967287
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients.
Beom SH; Kim DW; Sim SH; Keam B; Park JH; Lee JO; Kim TM; Lee SH; Heo DS
Cancer Res Treat; 2016 Jan; 48(1):88-97. PubMed ID: 25761482
[TBL] [Abstract][Full Text] [Related]
13. The Use of the Medical Dictionary for Regulatory Activities in the Identification of Mitochondrial Dysfunction in HIV-Infected Children.
Chernoff M; Ford-Chatterton H; Crain MJ
Case Studies Bus Ind Gov Stat; 2012 Oct; 5(1):17-31. PubMed ID: 23797349
[TBL] [Abstract][Full Text] [Related]
14. Cancer Phenotype Diagnosis and Drug Efficacy within Japanese Health Care.
Nishimura T; Kato H; Ikeda N; Kihara M; Nomura M; Kato Y; Marko-Varga G
Int J Proteomics; 2012; 2012():921901. PubMed ID: 22685658
[TBL] [Abstract][Full Text] [Related]
15. Proteomic biomarkers for acute interstitial lung disease in gefitinib-treated Japanese lung cancer patients.
Nyberg F; Ogiwara A; Harbron CG; Kawakami T; Nagasaka K; Takami S; Wada K; Tu HK; Otsuji M; Kyono Y; Dobashi T; Komatsu Y; Kihara M; Akimoto S; Peers IS; South MC; Higenbottam T; Fukuoka M; Nakata K; Ohe Y; Kudoh S; Clausen IG; Nishimura T; Marko-Varga G; Kato H
PLoS One; 2011; 6(7):e22062. PubMed ID: 21799770
[TBL] [Abstract][Full Text] [Related]
16. Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer.
Forsythe B; Faulkner K
Drug Saf; 2004; 27(14):1081-92. PubMed ID: 15554744
[TBL] [Abstract][Full Text] [Related]
17. National differences in reporting 'pneumonia' and 'pneumonia interstitial': an analysis of the WHO International Drug Monitoring Database on 15 drugs in nine countries for seven pulmonary conditions.
Koo LC; Clark JA; Quesenberry CP; Higenbottam T; Nyberg F; Wolf MK; Steinberg MH; Forsythe BH
Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):775-87. PubMed ID: 15654720
[TBL] [Abstract][Full Text] [Related]
18. A pilot study to build a database on seven anti-hypertensive drugs.
Fujita T; Miura Y; Mayama T
Pharmacoepidemiol Drug Saf; 2005 Jan; 14(1):41-6. PubMed ID: 15534857
[TBL] [Abstract][Full Text] [Related]
19. Building an ontology of adverse drug reactions for automated signal generation in pharmacovigilance.
Henegar C; Bousquet C; Lillo-Le Louët A; Degoulet P; Jaulent MC
Comput Biol Med; 2006; 36(7-8):748-67. PubMed ID: 16185681
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
